ABOUT US

Alethiomics Ltd is a discovery stage biotech company harnessing the power of single cell multi-omic technology to discover and develop life changing treatments for patients with blood cancer. A spin-out from the University of Oxford, Alethiomics was co-founded in 2021 by Prof. Adam Mead and Prof Bethan Psaila, both academic clinicians and expert haematologists. The company is supported by life sciences investor Oxford Science Enterprises. We are situated within Oxford University’s Old Road Campus, which offers a vibrant environment for biomedical research with ample collaboration opportunities.

REQUIRED EDUCATION & EXPERIENCE

· 5+ years of experience in industrial or academic research setting.
· Experience in developing biologic therapeutics, preferably in an oncology setting and with antibody drug conjugates.
· Track record of taking molecules from pre-clinical discovery, through IND enabling studies and into first-in-man studies.
· Strong scientific background, educated to a Ph.D. level within a life sciences discipline allied to an ability to critically evaluate scientific data and communicate to colleagues.
· Strong interpersonal and collaborative skills with demonstrated ability to build relationships and have effective collaborations with CRO and academic groups.

A key member of scientific team the Program lead – ADC development will develop and lead Alethiomics Research and Development strategies into optimisation of our antibody drug conjugate molecules. Reporting directly to the CDO, this role will focus on early discovery and pre-clinical design, evaluation and selection of ADCs for IND enabling studies and beyond.
The successful candidate will bring strong scientific and technical expertise within oncology and ADC design and be well-informed of the current developments in ADC design and clinical developments. They will have a proven track-record of successful advancement of assets from early discovery to clinic.